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Concise report
The reliability of immunoassays to detect
autoantibodies in patients with myositis is
dependent on autoantibody specificity
Sarah L. Tansley1, Danyang Li1, Zoe E. Betteridge1 and Neil J. McHugh 1
Abstract
Objectives. In order to address the reliability of commercial assays to identify myositis-specific and -associated
autoantibodies, we aimed to compare the results of two commercial immunoassays with the results obtained by
protein immunoprecipitation.
Methods. Autoantibody status was determined using radio-labelled protein immunoprecipitation for patients
referred to our laboratory for myositis autoantibody characterization. For each autoantibody of interest, the sera
from 25 different patients were analysed by line blot (Euroline Myositis Antigen Profile 4, EuroImmun, Lu¨beck,
Germany) and dot blot (D-Tek BlueDiver, Diagnostic Technology, Belrose, NSW, Australia). Sera from 134 adult
healthy controls were analysed.
Results. Overall commercial assays performed reasonably well, with high agreement (Cohen’s j >0.8). Notable
exceptions were the detection of rarer anti-synthetases with j< 0.2 and detection of anti-TIF1c, where j was 0.70
for the line blot and 0.31 for dot blot. Further analysis suggested that the proportion of patients with anti-TIF1c
may recognize a conformational epitope, limiting the ability of blotting-based assays that utilize denatured antigen
to detect this clinically important autoantibody. A false-positive result occurred in 13.7% of samples analysed by
line blot and 12.1% analysed by dot blot.
Conclusion. The assays analysed do not perform well for all myositis-specific and -associated autoantibodies
and overall false positives are relatively common. It is crucial that clinicians are aware of the limitations of the
methods used by their local laboratory. Results must be interpreted within the clinical context and immunoprecipi-
tation should still be considered in selected cases, such as apparently autoantibody-negative patients where anti-
synthetase syndrome is suspected.
Key words: myositis and muscle disease, autoantigens and autoantibodies, biomarkers, immunological tech-
niques, laboratory diagnosis
Introduction
Myositis-specific and -associated autoantibodies (MSAAs)
can be identified in 60% of adults and children with
myositis [1, 2]. They are widely acknowledged to be clin-
ically useful and can aid diagnosis, inform prognosis and
guide further investigations and treatment [1–3]. There are
a number of different established laboratory methods for
the detection of MSAAs in patient sera, each with their
own advantages and limitations. To date, immunoprecipi-
tation is considered the reference standard method. It has
been used to identify novel MSAAs, and MSAA specificity
can subsequently be confirmed using immunoprecipitation
blotting or mass spectrometry [4, 5]. However, immuno-
precipitation is an impractical method for widespread
diagnostic use, as it is relatively expensive, has low
throughput and requires specialist facilities along with staff
expertise. As a result, the availability of immunoprecipita-
tion for diagnostic purposes is limited to a handful of spe-
cialist centres worldwide.
Rheumatology key messages
. The assays tested do not reliably detect anti-TIF1c.
. The assays tested do not reliably detect rarer anti-synthetase autoantibodies.
. False positive results are relatively common.
1Department of Pharmacy and pharmacology, University of Bath,
Bath, UK
Submitted 5 September 2019; accepted 30 December 2019
Correspondence to: Sarah Tansley, University of Bath, Claverton
Down, Bath BA2 7AY, UK. E-mail: s.l.tansley@bath.ac.uk
C
L
IN
IC
A
L
S
C
IE
N
C
E
VC The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Rheumatology
Rheumatology 2020;0:1–6
doi:10.1093/rheumatology/keaa021
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/advance-article-abstract/doi/10.1093/rheum
atology/keaa021/5728764 by U
niversity of Bath user on 10 February 2020
Commercially available immunoassays offer the rapid
detection of MSAAs at low cost and without the need
for specialist expertise. As such, they allow the wide-
spread use of MSAA testing in order to take advantage
of the enhanced prognostic information MSAAs provide.
A number of different commercial immunoassays are
now available, but validation has been limited to using
small cohorts, with the majority of the MSAA specific-
ities underpowered for significant analysis. Concerns
have been raised regarding the validity of these alterna-
tive assays, particularly with regard to certain MSAA
specificities [6], and false positive rates may also be un-
acceptably high, with one study reporting antibody posi-
tivity in 22% of healthy controls (17% if anti-Ro52 was
excluded) [7].
We aimed to determine the ability of two different
commercially available testing methods to detect
MSAAs, using immunoprecipitation as the reference
standard.
Methods
Sample selection
Serum samples were selected from >3000 cases of
myositis previously analysed by immunoprecipitation in
our laboratory (for research or diagnostic purposes) and
reported as containing the MSAA of interest [1, 2].
Where possible, 25 samples of each autoantibody were
analysed, although, due to the rarity of some MSAAs,
smaller numbers of samples were used. Sera was
stored at 20C prior to analysis and the same sample
was used for all analyses. A total of 134 adult healthy
controls were also tested by dot blot and 76 by line
blot. Ethical approval was not required for this study.
IIF
IIF was performed on HEp-2 cells (Nova-lite, Inova, CA,
USA) according to the manufacturer’s instructions.
Samples were diluted to 1 in 100.
Immunoprecipitation
Sera (10 ll) was mixed with 2 mg protein-A-Sepharose
beads (Merck, Gilligham, Dorset) in immunoprecipitation
buffer (10 mM Tris-Cl pH 8.0, 500 mM NaCl, 0.1% v/v
Igepal) at room temperature for 30 min. Beads were
washed in immunoprecipitation buffer prior to the add-
ition of 120ll (35S)methionine-labelled K562 cell extract
in immunoprecipitation buffer. Samples were mixed at
4C for 2 h. Beads were washed in IP buffer and Tris-
buffered saline (10 mM Tris-Cl pH 7.4, 150 mM NaCl) be-
fore being resuspended in 50 ll SDS sample buffer
(Sigma-Aldrich, UK). After heating, proteins were fractio-
nated by 9% SDS-PAGE gels, enhanced, fixed and
dried. Labelled proteins were analysed by autoradiog-
raphy. Standard controls were included on each gel
(healthy control sera, anti-Jo-1, anti-U1RNP, anti-NXP2,
anti-PM/Scl, anti-Ro, anti-La, anti-AMA, anti-PL12, anti-
PL7, anti-Zo, anti-Mi-2, anti-Ku, anti-MDA5, anti-RNAPI/
III, anti-SAE, anti-U3RNP, anti-TIF1c, anti-Scl70 and
anti-SRP). Patients with bands at 140 kDa were identi-
fied as anti-NXP2, anti-MDA5 or neither by ELISA [8, 9].
Anti-HMGCR samples were confirmed by ELISA as
described in Tansley et al. [10].
Line blot
Line blots were performed according to manufacturer’s
instructions (Euroline Myositis Antigen Profile 4,
EuroImmun, Lu¨beck, Germany).
Dot blot
Dot blots were performed according to manufacturer’s
instructions (D-Tek, BlueDiver, Diagnostic Technology,
Belrose, NSW, Australia).
ELISA
In-house ELISAs were performed as detailed above to
confirm autoantibody specificity in particular circumstan-
ces following immunoprecipitation.
Immunoprecipitation blotting
Immunoprecipitation was performed as described
above using a non-radiolabelled K562 cell extract.
Immunoprecipitated proteins were fractionated by 9%
SDS-PAGE gels and transferred to nitrocellulose mem-
brane. The membrane was then probed with either
patient sera or a commercially available antibody
(Sigma-Aldrich).
Data analysis
Statistical analysis was performed using R Studio
0.99.903 (R Foundation, Vienna, Austria) [11]. The level
of agreement was assessed using weighted Cohen’s j.
Results
In total, 461 serum samples were analysed. Of these,
321 serum samples were analysed using both commer-
cial assays (25 anti-Jo1, 25 anti-Mi2, 25 anti-NXP2, 25
anti-MDA5, 25 anti-SAE, 25 anti-SRP, 25 anti-TIF1c, 21
anti-PL7, 20 anti-PL12, 14 anti-OJ, 10 anti-EJ, 9 anti-Zo,
3 anti-KS, 1 anti-Ha and 68 healthy controls). An add-
itional 74 serum samples were tested by line blot alone
(25 anti-HMGCR, 24 anti-Ku and 25 anti-PM/Scl) and 66
healthy controls were tested by dot blot alone.
Data on the presence of anti-Ro52 is not shown, as
this autoantigen is not detected by immunoprecipitation.
Sensitivity, specificity and level of agreement with
the reference test
Sensitivity varied considerably between MSAA specific-
ities for both assays. Interestingly, both assays per-
formed poorly in detecting the rarer anti-synthetase
autoantibodies as well as anti-TIF1c. KS and Ha are
included on the dot blot but were not analysed further
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2 https://academic.oup.com/rheumatology
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/advance-article-abstract/doi/10.1093/rheum
atology/keaa021/5728764 by U
niversity of Bath user on 10 February 2020
due to very small numbers of immunoprecipitation posi-
tive sera available. It is noteworthy that of the three anti-
KS samples and one anti-Ha sample available, none
tested positive on the dot blot assay. The sensitivity of
line blot and dot blot to detect MSAA previously identi-
fied by immunoprecipitation is shown in Tables 1 and 2,
respectively.
Specificity for each MSAA is shown in Tables 1 (line
blot) and 2 (dot blot), and was generally high. Overall,
13.7% of samples analysed by line blot and 12.1% by
dot blot produced a false positive result. An additional
6% of samples analysed by dot blot produced an ‘unre-
solved’ result, meaning that they were labelled as nei-
ther positive nor negative and could not be analysed
further. This occurred across autoantibody specificities
but was particularly common in anti-Mi2 sera, where
24% of samples were ‘unresolved’.
False positives
A total of 16.1% of healthy controls analysed by line blot
tested positive for an MSAA, excluding anti-Ro52. While
this is high, we note that positive results were generally
low level (10 of 11 false positive result in healthy controls
were 1þ only) and 4 of the 11 were anti-PM/Scl-75 posi-
tive in isolation (rather than the anticipated PM/Scl-75
and PM/Scl-100). It is likely therefore that these results
would be treated with a degree of suspicion in the clinical
context. On dot blot, the reported level of false positive
results in healthy controls was variable, ranging from 7 to
100 (positive range 1–100).
Looking at all false positive results, anti-Ku appeared
as a false positive most commonly on line blot [12 sam-
ples (3%)] and anti-SRP on dot blot [10 samples
(2.5%)]. Multiple autoantibody positivity was a common
feature of samples containing a false positive result:
55% of samples containing a false positive result by line
blot and 57% by dot blot were reported as having more
than one MSAA.
IIF was performed as described in all samples
where immunoprecipitation results differed from line blot
and/or dot blot findings. To better understand how the
commercial assay results might be interpreted in a non-
research setting, we analysed whether the correspond-
ing ANA pattern was consistent or inconsistent with that
reported by line/dot blot results.
TABLE 1 The performance of a commercial line blot compared with immunoprecipitation
Autoantibody (n) Line blot result Number of
samples with index
MSAA as false
positivea
Specificity Sensitivity Cohen’s j
False
negative
True
positive
Mi2a (25) 9 16 0 1 0.64 0.77
Mi2b (25) 17 8 7 0.98 0.32 0.37
Mi2a or Mi2b (25) 7 18 7 0.98 0.72 0.70
TIF1c (25) 10 15 2 0.99 0.6 0.70
MDA5 (25) 3 22 4 0.99 0.88 0.85
NXP2 (25) 4 21 0 1 0.84 0.91
SAE (25) 1 24 2 0.99 0.96 0.94
Ku (24) 0 24 12 0.97 0.97 0.78
PM/Scl-75 (25) 11 14 10 0.98 0.56 0.56
PM/Scl- 100 (25) 5 20 3 0.99 0.8 0.82
PM/Scl-75 or PM/Scl-100 (25) 4 21 13 96.2 0.84 0.69
Jo-1 (25) 3 22 4 0.98 0.82 0.85
SRP (25) 2 23 6 0.98 0.92 0.84
PL-7 (21) 5 16 5 0.99 0.64 0.75
PL-12 (20) 2 18 5 0.99 0.9 0.83
EJ (10) 4 6 0 1 0.6 0.76
OJ (14) 14 0 1 1 0 0
Zo (9) – – – – – –
KS (3) – – – – – –
Ha (1) – – – – – –
HMGCR (25) – – – – – –
Healthy controls (68) 0 0 11b – – –
Total (395) 54 199c 54d 0.62 0.78 0.41
The sensitivity, specificity and Cohen’s j coefficient for each assay are shown. Tests with j<0.8 are highlighted in bold.
aSome samples contained more than one false positive result. In total, 54 samples contained at least one false positive re-
sult. bOne sample was positive for anti-Ro52. The 11 listed were positive for myositis-specific autoantibodies. Anti-Ro52
were excluded from specificity calculations, as immunoprecipitation is unable to detect this autoantibody, which can be
found in healthy individuals. cSamples that contained a true positive result and no false positive result. dNumber of sam-
ples analysed containing at least one false positive result.
Reliability of immunoassays in myositis
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In those samples where an MSAA had been identified
by immunoprecipitation, the ANA pattern could often be
interpreted as consistent with the line/dot blot result.
This was usually because the immunoprecipitation result
and the line/dot blot result would be expected to pro-
duce the same ANA pattern. For example, in a patient
with anti-Jo1 on immunoprecipitation and a cytoplasmic
staining pattern on IIF, the pattern could be interpreted
as consistent with anti-SRP or other anti-synthetases
where these were identified on commercial immunoas-
says. For samples ‘false positive’ for at least one known
MSAA on line blot, IIF was consistent with this result in
40% of cases. For samples ‘false positive’ for at least
one known MSAA on dot blot, IIF was consistent with
the result in 75% of cases.
For healthy control samples, which were largely ANA
negative, IIF was less likely to be consistent with the
MSA identified by the commercial assay. For healthy
control samples ‘false positive’ for at least one MSAA
by line blot, no samples had an ANA pattern that could
further support this result. For samples ‘false positive’
for at least one MSAA by dot blot, 25% of samples had
an ANA pattern that could be consistent with this result
(all had a non-specific fine speckle nuclear staining
pattern).
Anti-TIF1c
Immunoprecipitation blotting was performed on 16 sam-
ples reported as containing anti-TIF1c by immunopreci-
pitation but negative on other assays. For 11 (69%) of
these samples, a prototype anti-TIF1c serum or com-
mercial anti-TIF1c was able to detect the immunopreci-
pitated antigen by blotting, confirming the presence of
the anti-TIF1c in the original sample. However, these 11
samples did not identify antigen immunoprecipitated by
the prototype anti-TIF1c serum or commercial anti-
TIF1c, suggesting that they target conformational epito-
pes that are not recognized in a denatured state (see
Supplementary Fig. S1, available at Rheumatology
online).
Discussion
Commercial assays to detect MSAAs are now in wide-
spread use worldwide. Limited validation, particularly for
TABLE 2 The performance of a commercial dot blot compared with immunoprecipitation
Autoantibody (n) Dot blot result Number of times
index MSA
occurred as
false positiveb
Specificity Sensitivity Cohen’s j
False
negative
‘Unresolved’a True
positive
Mi2 (25) 0 6 19 2 0.99 0.76 0.83
TIF1c (25) 18 1 6 5 0.99 0.24 0.31
MDA5 (25) 6 0 19 7 0.98 0.76 0.73
NXP2 (25) 2 2 21 5 0.99 0.84 0.81
SAE1 (25) 1 2 22 4 0.98 0.88 0.85
SAE2 (25) 10 2 13 5 0.98 0.52 0.58
SAE 1 or SAE2 (25) 1 2 22 8 0.98 0.88 0.78
Jo-1 (25) 4 0 21 2 0.99 0.84 0.87
SRP (25) 3 0 22 10 0.97 0.88 0.75
PL-7 (21) 0 1 20 2 0.99 0.95 0.93
PL-12 (20) 1 1 18 2 0.99 0.90 0.81
EJ (10) 1 0 9 3 0.99 0.90 0.77
OJ (14) 11 2 1 1 1 0.07 0.12
Zo (9) 9 0 0 2 0.99 0 20.02
KS (3) 3 0 0 2
Ha (1) 1 0 0 1
Healthy controls (134) 0 11 0 13c – – –
Total (387) 54 26 151d 46e 0.73 0.74f 0.48f
The sensitivity, specificity and Cohen’s j coefficient for each assay are shown. Tests with j<0.8 are highlighted in bold.
KS and Ha are included on the dot blot assay but were not analysed further due to very small numbers of immunoprecipi-
tation positive sera available. It is noteworthy that of the three anti-KS samples and one anti-Ha sample available, none
tested positive on the assay. aIn total, 15 patient samples and 11 healthy control samples were ‘unresolved’ by the assay
and a result was unavailable. These were counted as negative for the purposes of sensitivity, specificity and j calculations.
bSome samples contained more than one false positive result. In total, 46 samples contained at least one false positive re-
sult. cAn additional five samples were positive for anti-Ro52. The 13 listed were positive for myositis-specific autoantibod-
ies. Anti-Ro52 were excluded from specificity calculations because immunoprecipitation is unable to detect this
autoantibody, which can be found in healthy individuals. dSamples that contained a true positive result and no false-posi-
tive result. eNumber of samples analysed containing at least one false positive result. fIf ‘unresolved’ results are considered
to be false positives, specificity would be reduced to 0.60 and Cohen’s j to 0.34.
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rarer autoantibodies, has been a growing concern
among the myositis community [6, 12, 13]. Previous
studies in this area have been small, with low numbers
of sera containing individual MSAA specificities [6, 14,
15]. They have highlighted that the level of agreement of
line blot with immunoprecipitation is highly dependent
on autoantibody specificity [6, 14, 15]. By selecting sera
based on autoantibody specificity rather than analysing
a cohort, where some MSAA specificities may be very
low prevalence or absent, we have been able to clearly
demonstrate that the two commercially available assays
tested do not perform well for all MSAA specificities.
‘Problem’ MSAAs in both assays assessed are the rarer
anti-synthetase autoantibodies, where manufacturers
may have limited access to patient sera for assay devel-
opment and validation, and anti-TIF1c. With the excep-
tion of anti-MDA5, which we found to be reasonably
reliable, the ‘problem’ MSA specificities identified in our
study are similar to those reported by Espinosa-Ortega
et al. [6]. The difference with anti-MDA5 may be due to
the number of sera analysed, as the previous study
included just three patients with anti-MDA5. While we
found a higher number of MSAAs in control sera than
reported by Espinosa-Ortega et al., our findings are
comparable to those of Bundell et al. [7].
Anti-TIF1c is arguably one of the most clinically im-
portant MSAAs. It is the most common MSAA in those
with juvenile-onset myositis in the UK and USA, where it
is present in 20–30% of affected children, and in adults
it is strongly associated with the presence of an underly-
ing malignancy [1, 2, 16–19]. Anti-TIF1c is present in
7% of European adults with myositis and if this group
is to be appropriately targeted for malignancy screening,
it is crucial that anti-TIF1c can be accurately identified
[1]. Anti-TIF1c false negatives, which occurred in 40% of
samples analysed by line blot and 76% by dot blot,
could result in less rigorous malignancy screening in
adults. Furthermore, a significant proportion of patients
with juvenile-onset myositis would be incorrectly labelled
as autoantibody negative. Our data are in keeping with
the earlier findings of Espinosa-Ortega et al. [6] and sug-
gest that clinicians should not be reassured by a nega-
tive result obtained by these methods. As previously
reported by Targoff et al. [17] in 2006, we have shown
that anti-TIF1c frequently targets a conformational epi-
tope, thus limiting the utility of blotting-based assays
that use denatured antigen. In our experience, ELISA
appears to be more sensitive (in-house assay data not
shown) and a recent paper reports a high sensitivity and
specificity for a commercial ELISA to detect anti-TIF1c
compared with immunoprecipitation [20]. These assays
are disadvantaged by not being multiplex, but may be
necessary as an adjunct to other testing methods in
order to identify those patients with anti-TIF1c accurate-
ly. False negative results are important because, not
only will they influence prognostic information provided
to patients and potentially the approach to further inves-
tigation, but in the UK, NHS England requires the pres-
ence of a myositis-relevant autoantibody for affected
adults to access rituximab in the context of treatment-
resistant disease.
Multiplex assays such as those analysed in this study
simultaneously test for a number of key MSAAs. While
increasing efficiency, multiple testing has the disadvan-
tage of increasing the likelihood of false positive results.
While assays were all highly specific for individual
MSAAs, the overall false positive rate was high. MSAAs
are generally mutually exclusive and true multiple posi-
tives are exceptionally rare [1]. Multiple MSAA positivity
can be an important clue to false positive results. We
would also recommend ensuring that the ANA pattern
as determined by IIF is consistent with that expected for
the MSAA identified, as any discrepancy may point to a
false positive result. For those patients with negative
results by immunoassay, multiple MSAA positivity or
where the clinical picture does not fit with results
obtained, other methods including immunoprecipitation
should be considered to confirm MSAA status.
The limitations of this study include that we were un-
able to determine the interday or interlaboratory variabil-
ity of the assays tested, which was beyond our scope.
This does not detract from the concerns raised nor
change recommendations for when additional testing
should be considered.
In conclusion, myositis is a complex and heteroge-
neous disease and MSAAs provide an opportunity to
stratify patients and provide more personalized prognos-
tic information. Multiplex assays to detect MSAAs,
including those analysed in this study, are already part
of routine clinical practice. This study demonstrates the
limitations of such techniques, an understanding of
which is crucial in order for clinicians to interpret results
in the clinical context and in light of additional
investigations.
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